Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.

JPEN J Parenter Enteral Nutr · 2022 · PMC9292678 · PMID 34287970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a statistical trendno p-value reported

A statistical trend towards increased fat mass was found for 5‐mg apraglutide compared with the placebo (Table S2 ).

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.